Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection

Journal of Infectious Diseases

Volumn 190, Issue 3, 2004, Pages 588-597

  Mollenkopf, Hans Joachim ^a   Kursar, Mischo ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; BCG VACCINATION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; EXPERIMENTAL MODEL; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REINFECTION; SPLEEN CELL; TUBERCULOSIS;

ANIMALS; BCG VACCINE; CATTLE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE SERA; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; T-LYMPHOCYTES; TUBERCULOSIS; VACCINATION;

EID: 3242772928     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422394     Document Type: Article

References (55)

1. World Health Organization (WHO). Global tuberculosis control - surveillance, planning, financing. WHO report 2002. Geneva: WHO, 2002.
2. Orme IM. Immunology and vaccinology of tuberculosis: can lessons from the mouse be applied to the cow? Tuberculosis 2001; 81:109-13.
3. Kaufmann SH. A short history of Robert Koch's fight against tuberculosis: those who do not remember the past are condemned to repeat it. Tuberculosis 2003; 83:86-90.
4. Kaufmann SH. Immune response to tuberculosis: experimental animal models. Tuberculosis 2003; 83:107-11.
5. Roberts AD, Cooper AM, Belisle JT, Turner J, Gonzalez-Juarerro M, Orme IM. Murine model of tuberculosis. In: Kaufmann SH, Kabelitz D, eds. Immunology of infection. 2nd ed. London: Academic Press, 2002:433-62.
6. Calmette A, Guérin C. Nouvelles recherches experimentales sur la vaccination des bovides contre la tuberculose. Ann Inst Pasteur 1920; 34: 553-60.
7. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001; 22:160-8.
8. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-8.
9. Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983; 249:2362-9.
10. Bloom BR, Flynn J, McDonough K, Kress Y, Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 1994; 191:526-36.
11. Fine PE. Bacille Calmette-Guérin vaccines: a rough guide. Clin Infect Dis 1995; 20:11-4.
12. Rodrigues LC, Smith PG. Tuberculosis in developing countries and methods for its control. Trans R Soc Trop Med Hyg 1990; 84:739-44.
13. Roche PW, Triccas JA, Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol 1995; 3: 397-401.
14. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698-702.
15. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68:93-108.
16. Comstock GW. Tuberculosis: is the past once again prologue? Am J Public Health 1994; 84:1729-31.
17. Fine PE. BCG: the challenge continues. Scand J Infect Dis 2001; 33: 243-5.
18. Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 1996; 64:1-9.
19. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999; 17:915-22.
20. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284:1520-3.
21. Hess J, Kaufmann SH. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS Immunol Med Microbiol 1999; 23:165-73.
22. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39:2213-8.
23. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163:717-20.
24. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341:1174-9.
25. Schwartzman K. Latent tuberculosis infection: old problem, new priorities. CMAJ 2002; 166:759-61.
26. Enarson DA. Latent tuberculosis infection, its treatment, and the control and elimination of tuberculosis. Isr Med Assoc J 2002; 4:31-2.
27. O'Regan A, Joyce-Brady M. Latent tuberculosis may persist for over 40 years [letter]. BMJ 2001; 323:635.
28. Orme M. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis 2001; 5:589-93.
29. Barnes PF. Diagnosing latent tuberculosis infection: the 100-year upgrade. Am J Respir Crit Care Med 2001; 163:807-8.
30. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nature Med 2000; 6:1327-9.
31. Fensterle J, Grode L, Hess J, Kaufmann SH. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J Immunol 1999; 163:4510-8.
32. Arriaga AK, Orozco EH, Aguilar LD, Rook GAW, Pando RH. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002; 128:229-37.
33. van Pinxteren LAH, Cassidy JP, Smedegaard BHC, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98.
34. Botha T, Ryffel B. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 2002; 107:350-7.
35. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13:908-14.
36. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 2002; 185:401-4.
37. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 347:1860-6.
38. de Viedma DG, Marin M, Hernangomez S, et al. Tuberculosis recurrences - reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. Arch Intern Med 2002; 162:1873-9.
39. Kruuner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE, Mikelsaar M. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2002; 35:146-55.
40. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3:578-90.
41. de Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis 2003; 7:145-52.
42. Niemann S, Richter E, Rusch-Gerdes S, Schlaak M, Greinert U. Double infection with a resistant and a multidrug-resistant strain of Mycobacterium tuberculosis. Emerg Infect Dis 2000; 6:548-51.
43. Feng ZL, Castillo-Chavez C, Capurro AF. A model for tuberculosis with exogenous reinfection. Theor Popul Biol 2000; 57:235-47.
44. Dasgupta N, Tyagi JS. Identification of a restriction fragment length polymorphism associated with a deletion that maps in a transcriptionally active open-reading frame, orfX, in Mycobacterium tuberculosis Erdman. Tuber Lung Dis 1998; 79:75-81.
45. Manca C, Tsenova L, Barry CE, et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999; 162:6740-6.
46. Scanga CA, Mohan VP, Joseph H, Yu KM, Chan J, Flynn JL. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67:4531-8.
47. Kramnik IB, Apt AS, Moroz AM. Suppression of the immune response by lung cells in experimental tuberculosis [in Russian]. Biull Eksp Biol Med 1990; 110:77-80-9.
48. Saha B, Das G, Vohra H, Ganguly NK, Mishra GC. Macrophage - T-cell interaction in experimental mycobacterial infection - selective regulation of costimulatory molecules on mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune-response. Eur J Immunol 1994; 24:2618-24.
49. Orme IM, Collins FM. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy - requirement for T-cell-deficient recipients. J Exp Med 1983; 158:74-83.
50. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1:20-30.
51. Wangoo A, Sparer T, Brown IN, et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 2001; 166:3432-9.
52. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria - new potentials for conjugate vaccines? Scand J Immunol 2003; 58:119-28.
53. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99.
54. Briles DE, Hollingshead SK, Paton JC, et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 2003; 188:339-48.
55. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nature Med 2000; 6:955-60.